SnagRx offers compounded semaglutide from $69/month and tirzepatide from $119/month with price locked at every dose; BetterMe Rx offers plans from $145/month.

SnagRx and Vaylen both sell compounded GLP-1 care. SnagRx locks price at $69/mo semaglutide on a 12-month plan; Vaylen starts at $83.25/mo with prepay terms.

Unveiling Strategic Insights, Market Dynamics, and Competitive Tactics to Secure Dominant Market Position, Optimize Profit ...

Older female mice lived 12 percent longer on semaglutide and showed benefits that matched food restriction alone could not ...

Specialty coffee shops, focusing on quality above all else, have an opening to offer protein with more intent. Instead of ...

Le SMOP a beau être l’une des principales causes d’infertilité, les médecins se contentent bien souvent de recommander aux femmes concernées de perdre du poids.

A new study in Nature found that memory loss can be transferred via the gut. The culprit? A single species of bacteria that ...

Moonwalk Biosciences CEO Alex Aravanis argues the next chapter of obesity treatment won't be won by making GLP-1s slightly better, but by targeting ...

Novo Nordisk (NVO) stock dropped 9% Monday as the pharmaceutical company presented its 2030 growth strategy and pipeline targets to investors in London.

Obesity drug market shift: oral GLP-1s, monthly dosing and combo targets reshape LLY, NVO, VKTX & GPCR outlook.

The market for copycat versions remains substantial. By one estimate, roughly 1.5 million Americans take compounded GLP-1s. That's cause for concern.